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Abstract Skeletal muscle, a primary insulin target tissue, ex-
presses the GLUT5 fructose transporter. Although insulin has
no acute e¡ect on GLUT5 expression and function in muscle,
we show here that long-term (24 h) insulin treatment of L6
muscle cells induces a dose-dependent increase in GLUT5 pro-
tein (by up to two-fold), leading to a concomitant increase in
fructose uptake. The increase in GLUT5 expression and func-
tion was suppressed by inhibitors of gene transcription and pro-
tein synthesis, suggesting that insulin promotes de novo carrier
synthesis. Transfection of the GLUT5 gene promoter fused to
luciferase into L6 cells revealed that insulin induced a 1.8-fold
increase in GLUT5 promoter activity. Our ¢ndings indicate that
insulin is capable of increasing the abundance and functional
activity of GLUT5 in skeletal muscle cells and that this is
most likely mediated via activation of the GLUT5 promoter.
, 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Fructose is a major dietary sugar that, once absorbed
across the intestinal barrier, passes into the portal blood
stream, where it is delivered to the liver. The liver extracts
much of the absorbed fructose and is the principal site of
fructose metabolism. However, a signi¢cant proportion
(V30%) remains available for utilisation by peripheral tissues,
such as skeletal muscle and adipose tissue [1]. Indeed, whilst
glucose is the major hexose substrate for skeletal muscle, sev-
eral studies have demonstrated signi¢cant utilisation of fruc-
tose by this tissue. Early work showed that fructose was as-
similated in peripheral tissues at least as quickly as glucose [2],
and that in human muscle, glycogen synthesis rates were sim-
ilar after infusion of either glucose or fructose [3]. Further-
more, in the absence of insulin, physiological concentrations
of fructose have been shown to account for up to 30% of
glycogen synthesis in human skeletal muscle [4]. Together,
these studies indicate that fructose plays an important role
in overall carbohydrate metabolism in skeletal muscle and
that understanding how its transfer across the plasma mem-
brane is regulated may shed further insight into its metabolic
role in this tissue. We and others have shown that skeletal
muscle and adipose tissue express the GLUT5 fructose trans-
porter and that its expression is con¢ned to the plasma mem-
brane [5^8]. This cell surface localisation is in stark contrast to
that of the GLUT4 glucose transporter, which resides in intra-
cellular storage vesicles that are translocated to the plasma
membrane in response to an acute insulin challenge [9,10].
Whilst the insulin-dependent redistribution of GLUT4 is cen-
tral to the mechanism by which the hormone stimulates glu-
cose uptake in skeletal muscle, acute insulin treatment has no
e¡ect on the plasma membrane abundance of GLUT5 or
upon fructose transport [5,7]. However, there is no present
knowledge as to whether insulin may regulate GLUT5 expres-
sion levels in muscle cells.
In this study, we show that, like adult rat and human skel-
etal muscle [6,7], GLUT5 is also expressed in the plasma
membrane of cultured rat L6 skeletal muscle cells, where it
mediates fructose uptake. We demonstrate for the ¢rst time
that expression and function of this transporter can be en-
hanced by long-term exposure to insulin and that this is
most likely mediated by an insulin-induced increase in
GLUT5 promoter activity.
2. Materials and methods
2.1. Materials
All reagent-grade chemicals for bu¡ers were obtained from BDH
(Poole, Dorset, UK). Sterile trypsin/EDTA solution, fructose, cyto-
chalasin B (CB) and insulin were obtained from Sigma (Poole, Dorset,
UK). [14C]fructose and [3H]inulin were purchased from Amersham.
K-Minimal Essential Media (K-MEM), foetal calf serum, antimycotic/
antibiotic solution were from Life Technologies (Paisley, Renfrew-
shire, UK).
2.2. Cell culture
L6 muscle cells were grown as a monolayer as described previously
to the stage of myotubes in K-MEM containing 2% foetal calf serum
and 1% antimycotic/antibiotic solution at 37‡C in a humidi¢ed atmo-
sphere of 5% CO2, 95% air [11].
2.3. Fructose and glucose uptake in L6 muscle cells
L6 myotubes were exposed to insulin, insulin-like growth factor-1
(IGF-1), CB, cycloheximide and actinomycin D (Act D) at concen-
trations and periods indicated in the ¢gure legends. Cells were washed
three times in HEPES-bu¡ered saline (HBS, 20 mM HEPES, pH 7.4;
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140 mM NaCl; 5 mM KCl; 2.5 mM MgSO4 and 1 mM CaCl2) and
incubated for 30 min in warm HBS containing either 50 WM fructose,
0.12 WCi/plate [14C]fructose and 0.8 WCi/plate [3H]inulin (used to as-
sess non-speci¢c cell-associated radioactivity) or 10 WM 2-deoxy-[3H]-
D-glucose transport (1 WCi/ml, 26.2 Ci/mmol) as described previously.
Uptake was terminated by washing cells three times with ice-cold
saline prior to lysis in 50 mM NaOH. Cell-associated radioactivity
was determined by scintillation counting as described previously [5].
2.4. Subcellular fractionation of L6 muscle cells
Total L6 cell membranes, plasma and intracellular membranes were
prepared from L6 cells as described previously [11]. Protein content in
each membrane fraction was determined using the Bradford assay
with bovine serum albumin as standard [12].
2.5. SDS^PAGE and immunoblotting
Isolated membrane fractions from L6 cells were subjected to SDS^
PAGE on 10% resolving gels and immunoblotted as previously re-
ported [11]. PVDF membranes (Millipore, Bedford, MA, USA) were
probed with antisera against a peptide corresponding to the 13 car-
boxy-terminal amino acids of the rat GLUT5 protein (generously
provided by Dr. Y. Oka, University of Tokyo, Japan; [13]), the K1
subunit of the Na,K-ATPase (kindly provided by Dr. K. Sweadner,
Harvard University; [14]), and PKB (New England Biolabs, Herts,
UK). Primary antibody detection was performed using either horse-
radish peroxidase-conjugated anti-rabbit IgG, anti-mouse IgG (Diag-
nostics Scotland, Lanarkshire, Scotland, UK), or protein A (ICN) and
visualised using chemiluminescence Supersignal (Pierce).
2.6. RNA extraction and RT-PCR
Total RNA was extracted from L6 myoblasts and myotubes using
an RNA isolator kit (Qiagen). Reverse transcription and PCR were
performed using the Promega Access RT-PCR kit and GLUT5 spe-
ci¢c primers as described previously [6].
2.7. Transfection of L6 cells and luciferase assay
One day after seeding in six-well multi-dishes, L6 myoblasts were
transfected with 1Wg human GLUT5 promoter constructs [15], using
FuGENE 6 Transfection Reagent (Roche Diagnostics, Mannheim,
Germany). Cells were then incubated at 37‡C in a humidi¢ed atmo-
sphere of 5% CO2, 95% air for 24 h. After this period, cells were
incubated with 1 WM insulin for 3 h and lysed in a bu¡er containing
10% (v/v) glycerol, 1% (v/v) Triton X-100, 2 mM dithiothreitol, 2 mM
diaminocyclohexanetetraacetic acid and 25 mM Tris^phosphate pH
7.8 and centrifuged at 10 000Ug for 10 min. Supernatant was used
for the determination of luciferase activity, using a Luciferase Assay
System kit (Promega) and a TD-20/20 luminometer (Turner Designs),
as described previously [16]. Luciferase activities were expressed as
relative light units/mg of protein.
2.8. Statistical analyses
For multiple comparisons statistical analysis was performed using
one-way analysis of variance (ANOVA). Data analysis was performed
using GraphPad Prism software and considered statistically signi¢cant
at P values 6 0.05.
3. Results
3.1. Expression and subcellular localisation of GLUT5 in
L6 muscle cells
Since no information was available regarding the expression
of the GLUT5 transporter in L6 muscle cells, we initially
performed RT-PCR using rat-speci¢c GLUT5 primers [6]
with total RNA isolated from both L6 myoblasts and myo-
tubes. Fig. 1A shows that both produced a 496-bp speci¢c
PCR product that was not observed in samples incubated
without reverse transcriptase, indicating the presence of
GLUT5 mRNA. To assess whether GLUT5 protein was ex-
pressed, we immunoblotted total membranes prepared from
L6 myoblasts and myotubes, as well as crude rat jejunal mem-
branes (a positive immunoreactive control). Fig. 1B shows
that all the membrane fractions reacted with the GLUT5 anti-
body, demonstrating that GLUT5 protein was expressed in
L6 muscle cells. The variation in electrophoretic mobility ob-
served in crude jejunal membranes has previously been ob-
served [6,17] and is most likely due to di¡erences in N-linked
glycosylation of the protein. Since no signi¢cant di¡erences
were observed in GLUT5 abundance between L6 myoblasts
and L6 myotubes, it is unlikely that expression of this carrier
is modulated during cellular di¡erentiation (Fig. 1B). Fig. 1B
also shows that GLUT5 expression was restricted to the plas-
ma membrane in L6 myotubes; the weak signal observed in
the intracellular microsomal fraction most likely representing
cross-contamination between the two membrane fractions.
3.2. E¡ects of insulin on cellular GLUT5 abundance
Next we investigated whether GLUT5 expression and func-
tion could be modulated by long-term exposure of cells to
insulin. L6 myoblasts divide and grow until con£uence, at
which point they undergo spontaneous fusion to form multi-
nucleated myotubes [11,18]. This cellular di¡erentiation pro-
gramme takes approximately 7 days. As fully di¡erentiated
myotubes, cell division and DNA synthesis ceases [19]. We
thus elected to investigate the e¡ects of insulin on GLUT5
expression/function at day 6 of the cellular di¡erentiation pro-
gramme, at which time cells are V80^90% di¡erentiated. In-
cubating L6 myotubes with insulin for periods up to 24 h did
not cause any detectable increase in nuclei number (based on
nuclei count of several randomly picked visual ¢elds after
Giemsa staining, data not shown). Incubating L6 myotubes
with a supramaximal dose of insulin (1 WM) for 30 min had
no detectable e¡ect on GLUT5 abundance in plasma mem-
Fig. 1. Expression of GLUT5 mRNA and protein in L6 muscle
cells. A: Total RNA was prepared from L6 myoblasts and L6 myo-
tubes and used in RT-PCR with speci¢c GLUT5 primers, as de-
scribed in Section 2. The ampli¢ed product of 496 bp was detected
on a 1.4% agarose gel stained with ethidium bromide. Control reac-
tions were loaded lacking reverse transcriptase (3RT). B: Immuno-
blots showing GLUT5 abundance in rat jejunal crude membranes,
L6 myoblast and myotube total membranes, L6 myotubes plasma
membranes (PM) and L6 myotube internal membranes (IM). The
blots are representative of three separate experiments.
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branes. However, when insulin was present in the culture me-
dium for 24 h, we observed a dose-dependent increase in
GLUT5 protein abundance (Fig. 2A). The increase in
GLUT5 content after 24 h of 1 WM insulin treatment
(Vthree-fold, Fig. 2B) does not represent a generalised in-
crease in cellular protein expression, as under these circum-
stances insulin had no discernible e¡ect on the expression of
the K1 Na, K-ATPase subunit, another plasma membrane
transport protein [14]. Likewise, the cellular abundance of
protein kinase B (PKB), a predominantly cytosolic localised
protein kinase [20], was una¡ected by long-term insulin treat-
ment (Fig. 2A). Moreover, it is noteworthy that a sustained
(24 h) exposure to insulin has been shown previously not to
increase cellular GLUT4 expression in L6 cells [21].
3.3. Inhibitors of gene transcription and protein synthesis block
the insulin-dependent increase in fructose uptake
The dose-dependent increase in GLUT5 expression elicited
by chronic insulin treatment (Fig. 2A) was associated with an
attendant increase in fructose uptake (Fig. 3A). It is plausible
that the observed increases in GLUT5 expression and fructose
uptake that we observe in response to the higher hormone
concentrations used are as a result of insulin signalling
through the IGF-1, rather than the insulin receptor. It has
been previously reported that insulin (6 100 nM) and IGF-
1 (6 10 nM) signal largely (s 80%) through their respective
receptors in L6 myotubes [22^24]. Given that insulin enhanced
GLUT5 expression/function at concentrations as low as 10
and 100 nM (Figs. 2 and 3A), the observed e¡ects are likely
to be mediated via the insulin receptor. Nevertheless, to ad-
dress this issue further we assayed glucose and fructose uptake
in L6 myotubes after a 24-h incubation with IGF-1 (at con-
centrations between 0.3 and 10 nM). Incubation of L6 myo-
tubes with 10 nM IGF-1 has previously been shown to up-
regulate glucose transporter expression via the IGF-1 receptor
[23]. Consistent with this we found that chronic incubation of
muscle cells with IGF-1 induced an increase in glucose uptake
by over 2.5-fold, whereas there was no enhancing e¡ect on
fructose uptake (Fig. 3B). This ¢nding provides further sup-
port for the idea that signalling via the insulin, and not the
IGF-1, receptor is likely to direct changes in GLUT5 expres-
sion and function in L6 myotubes.
The characteristics with which glucose and fructose are tak-
en up in muscle cells can be further discriminated based on
the sensitivity of the transport process to an acute bout of
insulin treatment. Whilst long-term insulin exposure stimu-
lates fructose uptake, the hormone fails to elicit any increase
in the uptake of this sugar when presented to cells acutely
(Fig. 3C). In contrast, glucose uptake was stimulated by
over two-fold and was sensitive to inhibition by CB (Fig.
3C). We subsequently investigated whether the insulin-medi-
ated up-regulation in GLUT5 function was dependent upon
gene transcription and ongoing protein synthesis. To assess
this we pre-treated L6 myotubes with Act D, an inhibitor of
DNA transcription or cycloheximide, a protein synthesis in-
hibitor, 15 min prior to incubation with 1 WM insulin for 24 h.
Each inhibitor was present during the 24-h insulin treatment
period. Fig. 3D shows that the increase in cellular fructose
uptake induced by 24 h of insulin treatment was both tran-
scription- and translation-dependent. The inclusion of CB (10
WM) in the uptake assay failed to suppress the basal or the
insulin-induced increase in fructose uptake, consistent with
the suggestion that fructose uptake and the increase elicited
by insulin is unlikely to arise as a result of changes in the
expression of other transporters, such as GLUT1 and
GLUT4.
Fig. 2. E¡ect of acute and chronic insulin treatment on GLUT5 expression in L6 muscle cells. L6 myotubes were incubated with insulin for
times and concentrations indicated. L6 plasma membranes were prepared and 15 Wg membrane protein analysed by SDS^PAGE and immuno-
blotting as described in Section 2. A: Representative immunoblots from up to four separate experiments showing plasma membrane abundance
of GLUT5, the K1 subunit of the Naþ,Kþ-ATPase and cytosolic content of PKB in untreated (control) and insulin-incubated L6 myotubes.
B: Densitometric quanti¢cation of GLUT5 abundance in L6 plasma membranes from 24-h insulin-treated cells. GLUT5 signal density from un-
treated cells was assigned a value of 1. Values represent meansQS.E.M. (n=4). * Statistically signi¢cant change compared with control cells
(P6 0.05).
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The ¢nding that Act D suppresses insulin’s ability to up-
regulate fructose uptake suggests that the hormone may en-
hance GLUT5 gene expression largely through a transcrip-
tional mechanism, perhaps by stimulating the activity of the
GLUT5 promoter. To test this possibility, we transfected L6
cells with a human GLUT5 promoter fused to luciferase.
Since transfection e⁄ciency is low in fully di¡erentiated L6
myotubes, we used L6 myoblasts, which also express GLUT5
(see Fig. 1). Myoblasts were transfected with 1 Wg plasmid
containing GLUT5 promoter and then maintained at 37‡C
in a CO2 incubator for 24 h prior to study, so as to allow
su⁄cient promoter expression. Luciferase activity was found
to beV¢ve-fold higher when the GLUT5 promoter was fused
to the reporter gene, compared to cells transfected with a
promoter-less construct (Fig. 4A, inset). Fig. 4 shows that
incubation of transfected cells with insulin for 3 h led to a
two-fold activation in GLUT5-driven luciferase activity (Fig.
4A). An analysis of the GLUT5 promoter sequence revealed
the presence of a number of putative insulin responsive ele-
ments (IREs at regions around 31705, 31600, 3480 and
3320). Three di¡erent 5P-deleted promoter^luciferase con-
structs (which lacked these putative IREs) were transfected
into L6 cells. Fig. 4B shows that deletion to 3385 bp pro-
duced a 50% decrease in insulin-induced luciferase activity.
Almost complete inhibition of insulin-stimulated luciferase
activity was observed when cells were transfected with the
3272/+41-bp GLUT5 promoter construct (Fig. 4B).
4. Discussion
It is now evident that at least three of the classical facili-
tative sugar transporters, each having distinct biochemical
properties and functional roles with regard to maintenance
of sugar homeostasis, are expressed in insulin-sensitive tissues
(i.e. skeletal muscle and fat). GLUT1 and GLUT4 function as
the principal mediators of glucose uptake in these tissues [25],
the latter being responsible for the acute enhancement in glu-
cose uptake in response to insulin. In rat adipocytes, an acute
Fig. 3. E¡ects of insulin and inhibitors of gene transcription and protein synthesis on fructose uptake in L6 myotubes. A: L6 myotubes were
incubated with di¡erent insulin concentrations (between 1 nM and 1 WM) for 24 h prior to assaying fructose uptake as described in Section 2.
Uptake was expressed as a percentage increase over that measured in cells not treated with insulin. B: L6 cells were incubated with IGF-1 at
concentrations shown for 24 h prior to assaying fructose and glucose uptake. C: Fructose and glucose uptake were assessed in muscle cells in
the absence and presence of 100 nM insulin. D: Muscle cells were incubated with 3.5 WM cycloheximide (CHX) or 4 WM Act D 15 min before
treatment with 1 WM insulin for 24 h and fructose uptake assay. In some experiments 10 WM CB was included during the uptake assay. Values
represent meansQS.E.M. (n=3^4). * Statistically signi¢cant change compared with fructose uptake measured in untreated (control) cells
(P6 0.05).
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insulin challenge induces a marginal (15^20%) increase in
fructose uptake, which can be suppressed by CB, an inhibitor
of facilitative glucose transport, indicating that GLUT4 has a
modest capacity to mediate fructose uptake [5]. However, the
major fraction of total fructose uptake in both rat adipocytes
[5] and skeletal muscle [6] is insensitive to CB, suggesting that
most of the fructose is transported via another carrier. Het-
erologous expression studies in Xenopus oocytes indicate that
GLUT5 functions primarily as a fructose transporter and that
it is insensitive to inhibition by CB [26]. Given that the pres-
ence of fructokinase has previously been demonstrated in skel-
etal muscle [27,28], the uptake of fructose across the plasma
membrane of muscle cells via GLUT5 represents the ¢rst
committed step in fructose utilisation in this tissue. Whilst
glucose metabolism becomes predominant over that of fruc-
tose in the presence of insulin, physiological concentrations of
fructose contribute signi¢cantly to lactate production and can
account for up to 30% of total glycogen synthesis when cir-
culating insulin is low [4]. Such observations underscore the
important contribution that GLUT5 is likely to make in sup-
porting the use of fructose as a carbohydrate source in skel-
etal muscle.
Insulin not only exerts acute e¡ects on numerous responses
in skeletal muscle (e.g. stimulation of glucose transport), but
also imparts anabolic e¡ects in the long-term through regula-
tion of gene expression [29]. Our data indicate that insulin has
no acute stimulatory e¡ect on GLUT5 abundance or upon
fructose uptake in L6 muscle cells, but that both parameters
are enhanced by long-term exposure of cells to insulin in a
dose-dependent manner, and that this event relies upon gene
transcription. The observed e¡ects on transporter expression
were most notable at supramaximal concentrations of insulin
(1 WM). At these concentrations the hormone is also likely to
signal through IGF-1 receptors, although our data suggest
that signalling via the IGF-1 receptor per se is unlikely to
induce the up-regulation in GLUT5 expression/function that
we see in response to insulin. This proposition is further sup-
ported by the ¢nding that signi¢cant increases in transporter
function (V15^20%) were observed in response to insulin at
more physiological concentrations (i.e. 1 nM; Fig. 3A) that
are unlikely to invoke activation of the IGF-1 receptor. Our
¢ndings imply that a positive correlation exists between insu-
lin availability and GLUT5 expression and raise the interest-
ing possibility that circulating levels of insulin may be very
important for maintaining the normal expression and function
of GLUT5 in skeletal muscle. In this regard, it is worth stress-
ing that we have previously observed a profound reduction in
adipocyte GLUT5 expression in rats rendered diabetic with
streptozotocin, which lack the ability to synthesise insulin and
hence are hypo-insulineamic [5]. Furthermore, recent work in
our laboratory has shown that fat cell expression of GLUT5
is dramatically down-regulated during insulin resistance, con-
sistent with our suggestion that the hormone may provide a
tonic stimulus to help maintain GLUT5 expression (Lither-
land, Hajduch and Hundal, unpublished data). Since both
skeletal muscle and adipose tissue contribute signi¢cantly to
fructose utilisation [1], it is plausible that changes in GLUT5
expression elicited in response to insulin availability or insulin
resistance may have a signi¢cant impact on circulating fruc-
tose levels. Indeed, Kawasaki et al. [30] have reported very
recently that serum levels of fructose are 50% higher in dia-
betic than in non-diabetic or healthy human subjects. Whilst
the primary defect that gives rise to this increase in blood
fructose remains unclear, sustained increases in serum concen-
trations of the ketose have been associated with adverse met-
abolic changes such as glucose intolerance, hyperlipidaemia
Fig. 4. E¡ect of insulin on GLUT5 promoter activity in L6 myoblasts. A: L6 myoblasts were transfected with 1 Wg of di¡erent constructs of
pGLUT5-Luc. Cells were allowed to recover for 24 h post transfection with the GLUT5 promoter containing the 32500/+41 region prior to in-
cubation with 1 WM insulin for 3 h and assay of luciferase activity. The inset shows results obtained from L6 cells transfected with the GLUT5
promoter-less^luciferase (p-Luc) construct compared to cells transfected with the 32500/+41 promoter construct (pG5-Luc) in the absence of
insulin. B: Luciferase activity obtained in cells transfected with GLUT5 promoters encoding the 32500/+41, 3385/+41, 3338/+41 and 3272/
+41 regions following incubation with 1 WM insulin for 3 h. Luciferase values represent meansQS.E.M. from at least three separate experi-
ments. * Statistically signi¢cant change compared with untreated transfected cells (P6 0.05).
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[31] and non-enzymatic fructosylation of proteins [32], all fac-
tors implicated in the pathogenesis of diabetic complications.
Although previous studies have shown that chronic insulin
treatment up-regulates GLUT1 and glucose transport in L6
cells [21], our data represent the ¢rst demonstration that in-
sulin increases GLUT5 abundance and function via activation
of the GLUT5 promoter. This ¢nding raises the possibility
that the promoter driving the expression of the GLUT5
gene may possess insulin response elements. Indeed, sequence
analysis of the GLUT5 promoter reveals the presence of pu-
tative insulin-responsive motifs at 31705, 31620, 3535 and
3320 of the promoter. Removal of the promoter region be-
tween 32500 and 3385 bp (which results in the loss of three
of the four putative IREs) resulted in a 50% decrease in lu-
ciferase activity, suggesting the presence of critical response
element(s) that are indispensable for maintaining full GLUT5
promoter activity in this cell type. Furthermore, the trunca-
tion of the promoter up to 3272 bp resulted in 85% loss of
the insulin-stimulated luciferase activity, indicating that the
3338 to 3272 bp region of the promoter contains an addi-
tional insulin-responsive region (possibly the putative IRE
identi¢ed at 3320). The presence of hormone response ele-
ments in the GLUT5 gene promoter is not unprecedented.
Matosin-Matekalo et al. have shown in Caco-2 cells, a human
colon cancer cell line, that the GLUT5 gene promoter could
be activated by triiodothyronine (T3) and that the 3308/3290
region of the promoter contained a T3 responsive element
[15]. These workers also demonstrated that glucose could
up-regulate GLUT5 promoter activity in Caco-2 cells and
that a glucose-responsive element was likely to also be present
in the promoter [15]. However, in our cell-based studies in-
creased glucose or fructose availability over a 24-h period
does not enhance functional fructose uptake (data not
shown). This ¢nding is in line with our previous work showing
that feeding rats a fructose-enriched diet does not up-regulate
GLUT5 expression in rat skeletal muscle, but does so in the
intestine and kidney [6]. Such di¡erences in substrate-induced
regulation of GLUT5 may re£ect the distinct roles that the
carrier plays in tissues where the primary function is to absorb
or reabsorb fructose from the intestinal lumen and kidney
tubule respectively, as opposed to utilising the sugar for me-
tabolism in tissues such as muscle and fat.
In summary, there is now growing evidence that fructose
can be utilised as a source of fuel in tissues that are primary
targets of insulin action (i.e. skeletal muscle and adipose tis-
sue). The ability to utilise this sugar is inherently dependent
upon the expression of GLUT5 in these tissues. Whilst insulin
is unable to acutely up-regulate fructose utilisation in muscle,
it is likely to provide an important physiological stimulus that
is required for the constitutive expression of GLUT5 in this
tissue, probably by regulating the activity of the GLUT5 pro-
moter. The molecular mechanism involved in this process re-
mains currently unknown, but may involve modulated asso-
ciation of transcription factors with speci¢c promoter regions.
Indeed, use of TESS, a web-based search programme for tran-
scription element binding sites (http://www.cbil.upenn.edu/
tess), reveals putative binding sites for C/EBP, CREB,
PPAR, MyoD and myogenin within the GLUT5 promoter,
which may be involved in regulating the activity of the pro-
moter in response to changes in hormone and substrate avail-
ability. Exploring the molecular regulation of the GLUT5
promoter represents an interesting topic for future study
and may give further insights into the mechanism by which
insulin regulates the expression of GLUT5 and whether its
dys-regulation contributes to pathophysiological changes in
whole-body fructose metabolism.
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